CardiaTec Biosciences

Leverage high-dimensional human omics data to better navigate complex disease biology to discover novel and differentiated therapeutics for cardiovascular disease.

Funding Opportunity

£4.5M Seed raise

£4.5M Seed

Overview

CardiaTec is a TechBio company employing computational methods to decode the biology behind cardiovascular disease. The company leverages large and high-dimensional human omics data to identify novel and transformative therapeutics.

CardiaTec has built the largest proprietary human heart tissue multi-omics dataset and has access to 65 hospitals for whole human heart procurement, with paired electronic health records and blood samples

The company spun out of the Han Lab at the University of Cambridge and has brought together industry experts from leading organisations including Bristol Myers Squibb, Merck & Co, Cleveland Clinic and Recursion Pharmaceuticals.

The Challenge

Despite cardiovascular disease being the leading global cause of death, therapeutic innovation has been stagnant and underfunded. The complexity and multifactorial nature of cardiovascular disease pose significant challenges in understanding its underlying pathophysiology. Current investigation techniques provide a limited understanding of disease mechanisms, impeding the identification of effective and biologically relevant drug targets. Consequently, the clinical translation of associated drugs has been suboptimal, leaving a substantial unmet need for more effective treatments.

The Solution

CardiaTec is pioneering the development of the first multi-omics-driven drug target discovery platform specialised in cardiovascular disease. This approach is bolstered by a unique network comprising hospitals and academic institutions for the aggregation and generation of proprietary multi-omics data from human tissue samples; the company currently collects human heart tissue, bloods and EHRs from 65 hospitals across the US. The data spans genetics, epigenetics, transcriptomics, and proteomics. The infrastructure connects the biological entities together in a multi-layer network to represent the true disease biology and identify causal molecular mechanisms causing the disease. This allows for the discovery of novel and differentiated drug targets. Initially applied to coronary artery disease, the platform is now being expanded to include other indications.